SYN Synthetic Biologics, Inc. Stock Quote

SYN [AMEX]

Index	-	P/E	-	EPS (ttm)	-0.12	Insider Own	0.50%	Shs Outstand	132.04M	Perf Week	15.84%
Market Cap	29.84M	Forward P/E	-	EPS next Y	-0.20	Insider Trans	0.00%	Shs Float	-	Perf Month	3.24%
Income	-16.00M	PEG	-	EPS next Q	-0.04	Inst Own	8.30%	Short Float	-	Perf Quarter	-21.45%
Sales	-	P/S	-	EPS this Y	71.20%	Inst Trans	-4.65%	Short Ratio	1.29	Perf Half Y	-16.97%
Book/sh	0.49	P/B	0.46	EPS next Y	-28.60%	ROA	-20.50%	Target Price	1.62	Perf Year	-60.41%
Cash/sh	0.43	P/C	0.53	EPS next 5Y	-	ROE	-22.60%	52W Range	0.18 - 0.57	Perf YTD	-16.97%
Dividend	-	P/FCF	-	EPS past 5Y	54.80%	ROI	-	52W High	-61.21%	Beta	1.55
Dividend %	-	Quick Ratio	5.40	Sales past 5Y	-	Gross Margin	-	52W Low	23.39%	ATR	0.02
Employees	16	Current Ratio	5.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	57.19	Volatility	12.47% 7.76%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	75.50%	Profit Margin	-	Rel Volume	0.39	Prev Close	0.23
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 16 BMO	Payout	-	Avg Volume	868.37K	Price	0.22
Recom	2.00	SMA20	8.80%	SMA50	1.18%	SMA200	-26.46%	Volume	299,766	Change	-1.73%

Jan-06-17

Reiterated

FBR & Co.

Outperform

$5 → $6

May-06-16

Reiterated

FBR Capital

Outperform

$10 → $9

Feb-26-16

Initiated

FBR Capital

Outperform

$10

Oct-13-15

Initiated

RBC Capital Mkts

Outperform

Mar-16-15

Downgrade

Maxim Group

Buy → Hold

Mar-02-15

Reiterated

Maxim Group

Buy

$6 → $3

Mar-19-14

Reiterated

Maxim Group

Buy

$3 → $6

Sep-30-13

Initiated

Maxim Group

Buy

Jun-25-13

Initiated

Ascendiant Capital Markets

Buy

$2.25

May-16-22 08:00AM	Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results GlobeNewswire
May-10-22 12:24PM	Synthetic Biologics Posts Encouraging Safety Data on SYN-020 In Healthy Volunteers Benzinga +5.23%
08:00AM	Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial GlobeNewswire
May-09-22 08:00AM	Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial Results GlobeNewswire -8.03%
May-05-22 08:00AM	Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline GlobeNewswire
May-04-22 08:00AM	Synthetic Biologics Announces Presentation on VCN-11, a Novel Oncolytic Adenovirus Designed to Evade Neutralizing Antibodies at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) GlobeNewswire +5.42%
Mar-29-22 09:44AM	Synthetic Biologics' VCN-01 Shows Favorable Safety Profile, Clinical Activity In Early-Stage Cancer Study Benzinga -5.95%
Mar-28-22 04:05PM	Synthetic Biologics Announces Journal for ImmunoTherapy of Cancer Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients With Advanced Solid Tumors GlobeNewswire
Mar-23-22 08:00AM	Synthetic Biologics Announces Management Transitions in Support of Strategic Transformation GlobeNewswire
Mar-22-22 04:05PM	Synthetic Biologics to Participate in the Maxim 2022 Virtual Growth Conference GlobeNewswire -10.53%
Mar-16-22 04:05PM	Synthetic Biologics Reports 2021 Year End Operational Highlights and Financial Results GlobeNewswire +5.04%
Mar-11-22 08:00AM	Synthetic Biologics Completes Acquisition of VCN Biosciences GlobeNewswire
Mar-10-22 04:30PM	Synthetic Biologics to Host Conference Call and Webcast to Discuss 2021 Year End Operational Highlights and Financial Results GlobeNewswire
Feb-09-22 07:15AM	Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference PR Newswire
Feb-08-22 07:15AM	Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA PR Newswire -5.10%
Jan-26-22 04:05PM	Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022 PR Newswire
Dec-14-21 07:00AM	Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors PR Newswire
Nov-03-21 04:10PM	Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET PR Newswire
Oct-26-21 07:00AM	Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021 PR Newswire
Oct-21-21 07:00AM	Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase PR Newswire
Oct-06-21 04:30PM	Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum PR Newswire
Sep-21-21 04:30PM	Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum PR Newswire
Sep-10-21 12:19PM	7 Biotech Stocks to Buy That Have Millionaire-Maker Potential InvestorPlace +6.67%
Aug-05-21 04:10PM	Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET PR Newswire
Aug-03-21 07:00AM	Synthetic Biologics Expands Option for an Exclusive License Agreement with Massachusetts General Hospital PR Newswire
Jul-28-21 07:00AM	Synthetic Biologics to Report 2021 Second Quarter Operational Highlights and Financial Results on August 5, 2021 PR Newswire
Jun-29-21 07:00AM	Synthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial PR Newswire
Jun-14-21 03:35PM	Hedge Funds Are Nibbling On Synthetic Biologics Inc (SYN) Insider Monkey
May-26-21 07:00AM	Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards PR Newswire
May-05-21 04:10PM	Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results PR Newswire
02:30PM	Synthetic Biologics, Inc. to Host Earnings Call ACCESSWIRE
Apr-28-21 07:00AM	Synthetic Biologics to Report 2021 First Quarter Operational Highlights and Financial Results on May 5, 2021 PR Newswire
Apr-14-21 07:00AM	Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients PR Newswire
Apr-01-21 07:00AM	Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase PR Newswire
Mar-04-21 04:10PM	Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results PR Newswire -9.99%
02:30PM	Synthetic Biologics, Inc. to Host Earnings Call ACCESSWIRE
Feb-04-21 05:38AM	How Many Synthetic Biologics, Inc. (NYSEMKT:SYN) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
Dec-22-20 07:00AM	Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol PR Newswire +5.28%
Nov-24-20 07:00AM	Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American PR Newswire
Nov-16-20 07:00AM	Synthetic Biologics Engages A.G.P./Alliance Global Partners as Advisor to Assist in Evaluating Strategic Options PR Newswire
Nov-12-20 07:00AM	Synthetic Biologics Welcomes Senior Biotech Executive John Monahan, PhD, to Board of Directors PR Newswire +5.21%
Nov-10-20 04:15PM	Synthetic Biologics Reports 2020 Third Quarter Operational Highlights and Financial Results PR Newswire
02:45PM	Synthetic Biologics, Inc. to Host Earnings Call ACCESSWIRE
Nov-03-20 04:30PM	Synthetic Biologics to Report 2020 Third Quarter Operational Highlights and Financial Results on November 10, 2020 PR Newswire +5.53%
Oct-02-20 07:00AM	Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients PR Newswire -31.52%
Jun-30-20 07:00AM	Synthetic Biologics Announces Submission of IND Application to U.S. FDA for SYN-020 Intestinal Alkaline Phosphatase PR Newswire
Jun-15-20 11:41AM	Edited Transcript of SYN.A earnings conference call or presentation 5-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-27-20 07:00AM	Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020 to Treat and Prevent Age-Related Metabolic and Inflammatory Diseases PR Newswire +11.98%
May-13-20 12:20PM	Sýn hf.: Q1 2020 affected by the COVID-19 pandemic GlobeNewswire -8.73%
May-06-20 09:55AM	How Synthetic Biologics, Inc. (NYSEMKT:SYN) Can Impact Your Portfolio Volatility Simply Wall St.
May-05-20 04:15PM	Synthetic Biologics Reports 2020 First Quarter Operational Highlights and Financial Results PR Newswire
Apr-28-20 04:30PM	Synthetic Biologics to Report 2020 First Quarter Operational Highlights and Financial Results on May 5, 2020 PR Newswire
Mar-16-20 03:41PM	First human trial for coronavirus vaccine begins today: AP Yahoo Finance Video
Feb-26-20 12:29PM	Results in line with outlook GlobeNewswire
Feb-23-20 02:26PM	Edited Transcript of SYN earnings conference call or presentation 20-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Feb-20-20 04:15PM	Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results PR Newswire
Feb-07-20 04:30PM	Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American PR Newswire -5.75%
Feb-06-20 01:53PM	We Think Synthetic Biologics (NYSEMKT:SYN) Needs To Drive Business Growth Carefully Simply Wall St. +8.17%
Jan-07-20 07:00AM	Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients PR Newswire
Dec-30-19 05:54AM	Sýn hf.: Financial calendar 2020 GlobeNewswire
Dec-24-19 07:29AM	Sýn hf.: Landsdowne Partners International Limited - Major shareholder announcements GlobeNewswire
Nov-30-19 09:39AM	Is Synthetic Biologics Inc (SYN) Going To Burn These Hedge Funds ? Insider Monkey
Nov-27-19 04:30PM	Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan PR Newswire
Nov-21-19 12:21AM	Edited Transcript of SYN earnings conference call or presentation 4-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-14-19 11:23AM	Sýn hf.: Landsdowne Partners International Limited - Major shareholder announcements GlobeNewswire
Nov-06-19 12:02PM	Sýn hf.: Best operating profit of the year GlobeNewswire
Nov-04-19 04:10PM	Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results PR Newswire +6.28%
Oct-28-19 04:30PM	Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019 PR Newswire
Sep-26-19 07:00AM	Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) PR Newswire +12.24%
Sep-06-19 11:24AM	Does The Synthetic Biologics, Inc. (NYSEMKT:SYN) Share Price Tend To Follow The Market? Simply Wall St.
Sep-01-19 10:50PM	Edited Transcript of SYN earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-28-19 01:12PM	Sýn hf.: Financial results below expectations but positive outlook GlobeNewswire
Aug-20-19 09:46AM	Sýn hf.: Change in guidance GlobeNewswire
Aug-08-19 04:15PM	Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results PR Newswire
Aug-01-19 07:00AM	Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019 PR Newswire
Jul-01-19 07:00AM	Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards PR Newswire
May-27-19 03:14PM	Those Who Purchased Synthetic Biologics (NYSEMKT:SYN) Shares Three Years Ago Have A 99% Loss To Show For It Simply Wall St.
May-24-19 10:25AM	Sýn hf.: Notification of related party trading GlobeNewswire
May-22-19 12:55PM	Edited Transcript of SYN earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-08-19 06:02PM	Synthetic Biologics: 1Q Earnings Snapshot Associated Press
04:10PM	Synthetic Biologics Reports First Quarter 2019 Operational Highlights and Financial Results PR Newswire
Apr-30-19 04:30PM	Synthetic Biologics to Report 2019 First Quarter Operational Highlights and Financial Results on May 8, 2019 PR Newswire
Apr-20-19 03:38AM	Edited Transcript of SYN earnings conference call or presentation 27-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Feb-27-19 04:10PM	Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results PR Newswire
03:05PM	Sýn hf. : Q4 Investors presentation GlobeNewswire
02:55PM	Sýn hf. : Changes in management of Sýn hf. GlobeNewswire
02:53PM	Sýn hf. : Merged company completes its first full year under challenging market conditions GlobeNewswire
Feb-26-19 10:38AM	Sýn hf. : Sýn finalizes the merger of Hey P/F with Nema P/F GlobeNewswire
Feb-19-19 04:30PM	Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019 PR Newswire
Jan-03-19 07:00AM	Synthetic Biologics Announces First Two Patients Enrolled in Phase 2b Investigator-Sponsored PR Newswire
Dec-18-18 10:38AM	Edited Transcript of SYN earnings conference call or presentation 8-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Dec-04-18 12:00PM	Orchestra BioMed Appoints C. Evan Ballantyne as Chief Financial Officer GlobeNewswire
Nov-27-18 08:20AM	Report: Exploring Fundamental Drivers Behind Synthetic Biologics, Plexus, TG Therapeutics, Hortonworks, NorthWestern, and Archer Daniels Midland New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-22-18 09:10AM	New Trends in Healthcare Push Stocks Higher: 5 Picks Zacks
Nov-21-18 09:25AM	New Healthcare Trends Could Push Sector Stocks Higher ACCESSWIRE
07:00AM	Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development PR Newswire
Nov-08-18 06:02PM	Synthetic Biologics: 3Q Earnings Snapshot Associated Press
04:10PM	Synthetic Biologics Reports Third Quarter 2018 Operational Highlights and Financial Results PR Newswire
Oct-30-18 04:30PM	Synthetic Biologics to Report Third Quarter 2018 Operational Highlights and Financial Results on November 8, 2018 PR Newswire
Oct-18-18 08:40AM	Does Synthetic Biologics Inc (NYSEMKT:SYN) Have A High Beta? Simply Wall St.

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience